Immune Support Protocol
Thymosin Alpha-1 + LL-37
Strengthen immune function, support pathogen clearance, and modulate inflammatory responses
Overview
Combines a well-studied immune modulator with a potent antimicrobial peptide. Thymosin Alpha-1 (Ta1) enhances T-cell function and overall immune surveillance, while LL-37 (cathelicidin) provides direct antimicrobial activity and modulates innate immune responses. This stack is used for chronic infections, immune deficiency, and as an adjunct during illness.
Component Peptides
Immune modulator — enhances dendritic cell maturation, T-cell function, and NK cell activity. FDA-approved in over 30 countries (as Zadaxin)
Antimicrobial peptide — direct pathogen killing, biofilm disruption, and immune cell recruitment
Expected Timeline
Immune function improvements within 1-2 weeks. Reduced infection frequency at 4-8 weeks. Full immune optimization with ongoing use over 2-3 months.
Safety Notes
- Thymosin Alpha-1 has an excellent safety profile from decades of clinical use worldwide
- LL-37 may cause injection site reactions
- Caution in autoimmune conditions — immune stimulation may worsen flares
- LL-37 at high doses has shown hemolytic activity in vitro — stay within recommended doses
- Monitor for signs of immune overstimulation (fever, malaise)
Bloodwork Recommendations
- CBC with differential (lymphocyte subsets)
- NK cell activity panel
- Immunoglobulin levels (IgG, IgA, IgM)
- CRP and ESR
- CD4/CD8 ratio
- Vitamin D levels (cofactor for immune function)
Contraindications
- Active autoimmune disease in flare (relative contraindication)
- Organ transplant recipients on immunosuppressants
- Pregnancy or breastfeeding
- Known hypersensitivity
Evidence Assessment
Thymosin Alpha-1 has the strongest evidence base of any immune peptide — it is approved in over 30 countries for hepatitis B/C and as an immune adjuvant. Multiple clinical trials demonstrate efficacy. LL-37 is a naturally occurring human cathelicidin with extensive in vitro antimicrobial data and some clinical studies for wound healing and infections. The combination is theoretical but mechanistically sound.
References
- Romani L, et al. "Thymosin alpha1: an endogenous regulator of inflammation, immunity, and tolerance." Ann N Y Acad Sci. 2012;1270:45-50.
- Garrabou G, et al. "Thymosin-alpha 1 in infectious diseases." Ann N Y Acad Sci. 2007;1112:210-218.
- Vandamme D, et al. "A comprehensive summary of LL-37, the factotum human cathelicidin peptide." Cell Immunol. 2012;280(1):22-35.
Research Disclaimer: The information on this page is for educational purposes only and does not constitute medical advice. All products referenced are for in vitro laboratory research use only. Consult a qualified healthcare professional before beginning any research protocol.